# Juno Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/juno-therapeutics

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.junotherapeutics.com
- Total disclosed funding: $310M
- Latest round: Series B (Aug 5, 2014)
- Investors on record: 4

## About

Juno Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, specializing in developing innovative cell therapies for cancer treatment. The company focuses on harnessing the power of the immune system to provide targeted therapies.Founded in 2013, Juno Therapeutics is dedicated to the research and development of cell-based immunotherapies specifically for cancer. The company was founded by Michael Jensen and has undergone strategic pivots since inception. It secured USD 265 mn through an ADD-ON funding round led by Celgene in December 2014. Juno has completed a total of 6 deals.Juno Therapeutics develops leading-edge cell therapies targeting cancer treatments. These therapies aim to harness the immune system's capability to fight cancer, focusing on various types of blood cancers. The company is actively involved in clinical trials to test the efficacy and safety of its innovative treatments, catering to healthcare providers and patients globally.In 2017, Juno Therapeutics reported a revenue amount of USD 111.87 mn, with an EBITDA of USD -424.14 mn for the same year. Revenue generation primarily stems from its proprietary therapies developed for cancer treatment, ensuring access to innovative healthcare solutions.Juno Therapeutics plans to utilize the proceeds from its most recent funding round to enhance its research and development capabilities, specifically focusing on upcoming therapies aimed at addressing diverse cancer types. The company is looking to expand its market presence, targeting new geographical regions by 2025 to make its therapies accessible to a wider patient population. The additional funding will support ongoing clinical trials and the development of next-generation cell therapies.

## Funding rounds

- Series B, Aug 5, 2014, $134M — ARCH Venture Partners, Alaska Permanent Fund Corporation, Venrock, Bezos Expeditions
- Series A, Apr 24, 2014, $31M — Venrock, Bezos Expeditions
- Series A, Jan 13, 2014, $25M — Venrock, Bezos Expeditions
- Series A, Dec 4, 2013, $120M — ARCH Venture Partners, Alaska Permanent Fund Corporation

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Alaska Permanent Fund Corporation — Series A, Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series A, Series B
- Bezos Expeditions — Series A, Series B